Healthcare ❯Pharmaceuticals

Weight-Loss Drugs

Tirzepatide Market Performance Mounjaro Ozempic GLP-1 Agonists GLP-1 Drugs Obesity Treatment

Eli Lilly Lowers 2024 Revenue Forecast as Weight-Loss Drug Sales Lag

The pharmaceutical company revises Q4 revenue estimates down by $500 million, citing slower-than-expected sales of key drugs Mounjaro and Zepbound.

Eli Lilly and Amazon Partner to Deliver Weight Loss Drug Zepbound Directly to Consumers

Drugmakers Raise Prices for Over 700 Medications, Including Popular Weight-Loss Drugs Ozempic and Mounjaro